| Logo | Name | Σ | Employees | ||
|---|---|---|---|---|---|
 | Parc Científic de Barcelona [Automatic translation follows] Where Science becomes Business Located in the knowledge campus, the PCB provides you with basic ordinary services and a privileged environment for networking. More than 2,700 highly qualified researchers work at the PCB; join our community! | 5 | 2 | 3 | 107 |
 | centdegrés Creative Activists Since 1988 We believe in bold creativity. For thirty years, we’ve focused all our energies on helping our clients win their battles, improve their impact, and challenge the status quo. Through design. We hunt down the best conditions for your projects in order to create unique personalised design and make a new kind of impact. Anything that will only achieve a partial result is a waste of time. We live by the certainty that there is no such thing as “hype”, freedom and creativity are crucial aspects of our approach. We have continuously created exceptional experiences, brands, products … | 2 | 2 | 2 | 63 |
 | VERTEXA Digital Therapeutics [Automatic translation follows] VERTEXA is an immersive therapeutic game, in virtual reality. Let’s digitalize health! VERTEXA digital therapy (Virtual Reality Therapy Exposition in Anorexia) aims to use virtual reality as a support tool in the form of a gamified and immersive psychoeducational course in patients suffering from eating disorders (anorexia, bulimia). The use of digital tools and new technologies now allow an innovative, personalized, motivating and accessible approach regardless of where our patients are cared for. The VERTEXA tool is intended to be autonomous: the patient is involved in his or her care. He will be immersed in a soothing … Type: | 21 | 2 | 21 | 4 |
 | Drug Discovery World The Global Business Review of Drug Discovery and Development Welcome to our LinkedIn page. This is where we will share original content from the DDW team and industry experts, as well as daily news and other company updates. Published for over 20 years, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry … Type: | 19 | 2 | 17 | 9 |
 |  GFBiochemicals GFBiochemicals is on a mission to create a more sustainable future and transform the chemicals industry GFBiochemicals is a biochemical company that specializes in the research, development, production and business development of bio-based and renewable chemicals. We provide high-quality, bio-based chemicals to businesses across the world. Our focus is green chemistry – a sustainable alternative to traditional oil-based chemistry. Our technology is proprietary and has been developed in-house over many years. GFBiochemicals is headquartered in Paris, France and has subsidiaries in Geleen, the Netherlands and Minneapolis, USA. GFBiochemicals acquired Segetis, in 2016, as part of our growth strategy to integrate … Type: | 5 | 2 | 3 | 33 |
 |  BrightHeart Advancing prenatal ultrasound screening with AI At BrightHeart, we believe every single fetal ultrasound screening exam should be performed with the highest level of accuracy, so each mother and baby receive the highest possible quality of care. Type: | 2 | 2 | 1 | 12 |
 | Tenpoint Therapeutics Ltd Vision-restoring engineered cell-based therapeutics & in vivo reprogramming. Tenpoint Therapeutics is a vision-restoring engineered cell-based therapeutics company. We are embracing a new opportunity to fundamentally reshape the future for people with ocular diseases. We have an ambitious goal with global impact. Type: | 2 | 2 | 0 | 28 |
 | Groupe Stratos Groupe STRATOS is an entrepreneurs community providing companies with custom-made solutions. Groupe STRATOS is an entrepreneurs community providing companies with custom-made solutions. Our community is composed of entrepreneurs with expertise on a specific topic and each single member is/was an entrepreneur. Groupe STRATOS was founded in 2020 with the merger of 2 other companies created 10 & 20 years ago. About our advisory activiy : - Fund raisings through our network of +1 000 investors (France & International) - Mergers & Acquisitions - Financial audits (M&A, valuation of companies, due diligence...) - Financial analysis - Strategy & business development - … Type: | 54 | 2 | 54 | 8 |
 | Sitryx Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therapies Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at … Type: | 3 | 2 | 3 | 51 |
 | GIMLI Leverage Real World Evidence in oncology Gimli empowers medical professionals to structure medical data. We extract and structure data directly from the EMR to streamline RWD, allowing the generation of strong RWE. Ask us for a demo! Gimli is a Startup working with university hospitals, pharmaceutical companies, data analytics providers, and startups. Type: | 22 | 2 | 11 | 7 |
 | IMS (Institut du Médicament de Strasbourg) [Automatic translation follows] Interdisciplinary Thematic Institute of the University of Strasbourg The Strasbourg Medicine Institute responds to the challenges of the medicines sector: producing cutting-edge research up to the pre-clinical stage, promoting technological innovation through the creation of start-ups and training the new generation of researchers in management of drug innovation. Type: | 13 | 2 | 7 | 6 |
 |  Sustainability Consult Credible sustainability & bioeconomy communications. Led by Conscious Business Leader Kathryn Sheridan since 2008. Sustainability Consult is dedicated to raising Credibility and Visibility for organisations worldwide. We are the leading bioeconomy communications and PR agency, based in Brussels, operating internationally. A trusted partner and recognised source for the media, Sustainability Consult has a proven track record in brand building, corporate communications and PR. We offer a full service of high-level consultancy services, from PR to communications and online strategy, through to issues management and crisis communications, as well as events, reports and media monitoring. We tweet @SustConsult. Follow us on … Type: | 9 | 3 | 6 | 1 |
 | ENYO Pharma Developing therapeutics for diseases with impaired kidney function ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome, and liver diseases (such as Non-Alcoholic SteatoHepatitis, NASH). Liver-related infectious diseases such as chronic Hepatitis B and Hepatitis D are also addressed with Vonafexor. Type: | 8 | 3 | 5 | 31 |
 | Wellcome Sanger Institute The Wellcome Sanger Institute is a world leading genomics research centre. The Wellcome Sanger Institute is a world leader in genomics research. We generate and analyse data at a scale not easily possible elsewhere. We apply and explore genomic technologies to advance the understanding of biology and improve health. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve … Type: | 4 | 3 | 1 | 1,415 |
 | LifeArc Transforming promising life science ideas into medical breakthroughs that change patients’ lives. LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives. We are self-funding and specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. This includes Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) … Type: | 17 | 3 | 12 | 380 |
 | The Francis Crick Institute We are a biomedical discovery institute breaking down barriers between disciplines. The Crick is a distinctive biomedical research institute. We’re committed to advancing, promoting, and sharing understanding of human health and disease. We do that by attracting talented and ambitious people from all disciplines and backgrounds and giving them the support and freedom they need to succeed. Inside the Crick, you’ll discover scientists working to stretch the very limits of what we know about how life works. Their research holds the key to answering fundamental questions about human health and disease. Our bold and innovative research projects bring together scientists … Type: | 10 | 3 | 6 | 1,619 |
 | Abingworth Life Science Investing Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022. Investing in … Type: | 5 | 3 | 2 | 42 |
 | Labiotech.eu The leading digital media covering global biotech innovation Labiotech.eu is the leading digital media covering the global biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Join them now and enjoy reading our stories! "We are building the Next Generation of Digital Media for Biotech" Philip & Joachim, Founders of Labiotech.eu Biotechnology, Life science, News, and Media Type: | 24 | 3 | 21 | 10 |
 | Syncona Limited Building the next generation of healthcare companies Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 20- 25 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders. We take a long-term view, underpinned by a strategic capital base which enables us to maintain significant ownership positions in our companies and provides us with control and flexibility over the management of … Type: | 9 | 3 | 1 | 51 |
 | Gilde Healthcare Specialized healthcare investor in both Healthcare Venture & Growth as well as Healthcare Private Equity, managing €2.5B Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Gilde Healthcare's lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare's venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are … Type: | 5 | 3 | 2 | 62 |
 | GENFIT Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs. GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, … Type: | 7 | 3 | 5 | 172 |
 | RELEVATION The Global digital fundraising Summit for PropTech startups Relevation.org is the global digital investment summit in UrbanTech; a 2 days event of match-making between investors (BA, family offices, VC, CVC...) and startups across all the stages of maturity in fund raising process Type: | 21 | 3 | 20 | 3 |
 | ProQR Therapeutics Advancing our proprietary AxiomerTM RNA-editing platform technology Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/ RNA therapeutics, Drug development, Rare Diseases, Genetic Diseases, Orphan drugs, Pharmaceuticals, and RNA editing Type: | 3 | 3 | 1 | 163 |
 | Artios Taking control of the DNA Damage Response (DDR) Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. … Type: | 7 | 3 | 0 | 113 |
 | Biotalys Reinventing food protection We are a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Based on our ground-breaking technology platform, Biotalys is developing a broad pipeline of effective and safe products with novel modes of action, addressing key crop pests and diseases across the whole value chain, from soil to plate. Biotalys’ unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. We are … Type: | 6 | 3 | 5 | 69 |
 | Asabys Partners Investing in Life. Investing in Science. Investing in Future. Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in … Type: | 18 | 3 | 15 | 12 |
 | Endpoints News The biopharma world is here Endpoints is the biopharma world's leading source for breaking news, smart analysis and exclusive access. We cover the intersection of science, money and power in the world's most innovative industry, and are a part of the Financial Times' FT Specialist group. Biotechnology, News, Drug Development, and Pharmaceuticals Type: | 20 | 3 | 19 | 62 |
 | BIOWEG Revolutionizing the Future of Bio-ingredients BIOWEG, founded in 2019 in Germany, is a purpose-driven organization powered by conscious ChemDesign. We match Bio-innovation to business problems. We explore and combine biotechnology, material science, and molecular simulation learning to create advanced sustainable bio-based high-performance ingredients. Our ingredients are 100% animal free, globally scalable, and sustainably produced without harsh chemicals. We work with results-oriented, forward-thinking companies, and consumer brands with global scale in the cosmetics, personal care, nutraceuticals, agricultural coatings, and food/beverage sectors who desire highly differentiated and sustainable science-based ingredient technologies. Material Science, Fermentation , Green Chemistry, Alternative Ingredients, Biobased Materials, Biodegradabe, … Type: | 22 | 3 | 2 | 20 |
 | Apollo Global Management, Inc. Apollo is a high-growth alternative asset manager. Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three investing strategies: yield, hybrid, and equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a … Type: | 16 | 3 | 6 | 4,034 |
 | Sixth Street Global investors developing themes and offering solutions to companies across all stages of growth Sixth Street is a global investment firm with over $75 billion in assets under management and committed capital. We use our long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Sixth Street is dedicated to cross-platform collaboration at scale. We have more than 550 team members including over 200 investment professionals operating across our global locations. We invest through our diversified, collaborative investment platforms: TAO, Growth, Direct Lending, Strategic Capital, Fundamental Strategies, Infrastructure, … Type: | 4 | 3 | 1 | 693 |
 | Janus Henderson Investors We’re a global asset manager dedicated to investing in a #BrighterFutureTogether for our clients. Janus Henderson’s mission is to help clients define and achieve superior financial outcomes through differentiated insights, disciplined investments and world-class service. We’re dedicated to investing in a brighter future together. Formed in 2017 from the merger between Janus Capital Group and Henderson Global Investors, we have over 89 years’ experience in investing, underpinned by a culture deep rooted in research. With over 340 investment professionals worldwide, who meet regularly to share insights, we’re able to offer a world-class service providing tailored solutions and the personal touch … Type: | 3 | 3 | 0 | 2,938 |
 | Italian Tech Alliance [Automatic translation follows] Formerly VC Hub Italia, it is the association of Venture Capital, investors in innovation, startups and innovative SMEs Italian Tech Alliance is the reference association for: - venture capital funds; - investors in innovation; - innovative startups and SMEs. The objective of the association is to promote the development of the technology and innovation ecosystem in Italy, working closely with institutions. The contents of the Italian Tech Alliance disseminate news, opportunities and interesting reports for private and public stakeholders who work for the economic and social growth of the country. The following currently sit on the Board … Type: | 7 | 3 | 3 | 15 |
 | Wellington Management Trusted adviser to investors worldwide For almost 100 years, we have chosen to do things differently, including the way we structure our ownership model, organization, and investment platform. Critically, we know that the best investment ideas are found when a diverse workforce is encouraged to bring forward unique perspectives. Wellington Management is one of the world’s largest independent investment management firms, serving as a trusted adviser to over 2,400 clients in more than 60 countries. We manage more than US$1 trillion for pensions, endowments and foundations, insurers, family offices, fund sponsors, global wealth managers, and other clients. As a private … Type: | 3 | 3 | 0 | 3,616 |
 | Bioptimus We build foundation models that will transform biology. We use cutting-edge technology to transform multiscale data into actionable representations to fuel breakthrough discoveries. Join us on our mission to build foundation models that transform biology. artificial intelligence, biology, and foundation models Type: | 4 | 3 | 3 | 13 |
 | GV (Google Ventures) Launched as Google Ventures in 2009, GV supports innovative founders moving the world forward. GV supports innovative founders moving the world forward. We invest across the life sciences, consumer, enterprise, crypto, climate, and frontier technology sectors. With Alphabet as a sole limited partner, GV operates on long time horizons and deals in decades, not rounds. Our operating partners help startups at the earliest stages of company-building across design, equity, diversity & inclusion, talent, and engineering. We also help startups interface with Google, providing unique access to the world’s best technology and talent. Launched as Google Ventures in 2009, GV has … Type: | 12 | 4 | 6 | 240 |
 | Interaction Healthcare [Automatic translation follows] Your strategy deserves the best treatment 100% digital agency specializing in the field of health. Founded in 2008, Interaction Healthcare’s know-how is based on 4 pillars: - digital strategy consulting; - web and social media solutions; - mobile solutions and new interfaces; - digital medical simulation and serious game. Interaction Healthcare designs and develops digital communication and e-training tools for the pharmaceutical industry, university hospitals, simulation centers, learned societies, patient associations, healthcare professionals and the general public. Recognized as an innovative company by the Oséo Excellence 2012 network and partner of INRIa, a digital research laboratory, the … Type: | 42 | 4 | 39 | 15 |
 | Invyo Europe's leading data platform for data-driven investors (Venture Capital / Private Equity / Family Office) Since 2018, INVYO has been the trusted partner for investors in private equity, venture capital and family offices. We are a reference platform in Europe, propelling investors towards a data and tech-driven investment model thanks to AI. Our sector expertise harnesses your data to boost your human and financial performance. - French publisher - More than 50 client funds - 16 data experts - 2 offices: Paris & Madrid - SaaS solutions Our mission : At INVYO, we unleash the potential of investment teams through … Type: | 53 | 4 | 53 | 20 |
 | mind Health [Automatic translation follows] The strategic information service dedicated to the digital transformation of healthcare industries. mind Health is a B2B service offering dedicated to the transformation of health industries, innovation and the transformation of the value chain in the health ecosystem. Offering information, monitoring and analysis, mind Health is aimed at all the players and sectors that make up this ecosystem: pharmaceutical and medical device industries, electronics, IT and telecoms, mutual funds and insurance, healthcare services. public and private, service providers... Type: | 72 | 4 | 70 | 4 |
 | HarperCollins Publishers Publishing great authors since 1817. HarperCollins Publishers is the second-largest consumer book publisher in the world. Headquartered in New York, HarperCollins has publishing operations in 17 countries. With two hundred years of history and more than 120 branded imprints around the world, HarperCollins publishes approximately 10,000 new books every year in 16 languages, and has a print and digital catalog of more than 200,000 titles. Writing across dozens of genres, HarperCollins authors include winners of the Nobel Prize, the Pulitzer Prize, the National Book Award, the Newbery and Caldecott Medals, and the Man Booker Prize. HarperCollins is a subsidiary of … Type: | 15 | 4 | 11 | 4,129 |
 | BIOTECHFINANCES [Automatic translation follows] 1st weekly specialist information, biotech, medtech, e-health, finance published by Jacques Bernard Taste PRESENTATION The weekly Biotech Finances letter approaches from an economic and financial angle all questions linked to the development of the biotechnology sector and more broadly life sciences. Our target readership is mainly composed of biotechnology companies focused on health and the development of new therapies and new treatments for diseases, pharmaceutical companies (big pharma and other laboratories), investors, business angels, funds investments, venture capital, specialists in the biotech sector, institutional investors, legal advisors, development experts, and service providers and equipment suppliers. Our articles … Type: | 13 | 4 | 3 | 9 |
 | Milano Finanza [Automatic translation follows] The best of economic-financial information, at your disposal, always. MF-Milano Finanza is the national financial and economic newspaper, with the primacy of information on the stock market, economy, investments and markets. A direct line to Piazza Affari and the main world stock exchanges. With dedicated sections: Online Trading, Technical Analysis, ETF, Covered Warrants, Private Equity, Shipping & Logistics and on Saturdays with Milano Finanza important insights into the world of managed savings, securities and real estate investment. The correctness, truthfulness and authoritativeness of the newspaper are recognized by the target and by professionals both at a national … Type: | 4 | 4 | 0 | 282 |
 | Latham & Watkins Latham & Watkins is a global law firm with more than 3,500 lawyers in its offices located in Asia, Europe, the Middle East and the United States. The firm has internationally recognized practices in a wide spectrum of transactional, litigation, corporate and regulatory areas. Our success is grounded in our devotion to the collaborative process, which reaches across global offices and practices and draws upon our deep subject matter expertise, an abiding commitment to teamwork and a powerful tradition of creative lawyering. Follow us on Twitter @lathamwatkins Join us on Facebook www.facebook.com/lathamwatkins Subscribe to us on YouTube http://youtube.com/lathamwatkinsglobal Content may … Type: | 8 | 4 | 4 | 7,591 |
 | Evonik Leading in specialty chemicals and beyond to make the world a better place. Evonik is one of the world’s leading specialty chemicals companies. While we don’t produce electric cars, aircraft, medications or 3D printers, Evonik is part and parcel of these and many other end products. That’s because we contribute the small things that make a big difference. We make electric car batteries perform better, aircraft greener, medications more effective and 3D printers more efficient. In short: We think beyond the bounds of chemistry to make the world a better place. Today and tomorrow. We are an international group with … Type: | 11 | 4 | 5 | 13,487 |
 | McDermott Will & Emery A global law firm helping propel today’s most respected, dynamic and important organizations. McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 20+ locations globally, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve. Attorney Advertising. Prior results do not guarantee a similar outcome. Type: | 10 | 4 | 6 | 3,144 |
 | LSX LSX is a growing influential community of senior life science decision makers. We are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. We are determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. Our community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas. We bring deals to life., LSX is the network for life science executive leaders. Take a … Type: | 30 | 4 | 20 | 5 |
 | Cambridge Innovation Capital A leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies. Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. CIC currently manages over £500 million and has invested in 30+ companies. We invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics. IP Commercialisation, Venture Capital, healthcare, … Type: | 13 | 4 | 5 | 32 |
 | Startup Insider [Automatic translation follows] The most important news, trends and investments from the German startup scene. With Startup Insider, a new industry portal is being created for the startup scene in Germany, Austria and Switzerland. Here you can find news from all regions and industries as well as an overview of the most important players and events in the German-speaking startup world. Startup Insider's mission is to support startups on their path to success. We help startups and grow-ups make contacts with investors and customers, find new employees or gain media visibility at events or online, in print or newsletters. Startups, … Type: | 29 | 4 | 26 | 36 |
 | PE Cube SaaS for Private Equity with Clarity PE Cube is a SaaS solution for each team member of Private Equity management companies to optimize fund management’s performance while enabling a rich, reliable and transparent communication towards each of its stakeholders. PE Cube is based on 20 years of Private Equity practice and on the key-belief that data is crucial to each level of fund management. This is why PECube is designed to ensure flawless end-to-end processing to express the full potential for monitoring and steering fund management activity. Each general partner member is thus equipped to ensure reliability, security and accessibility … Type: | 40 | 4 | 40 | 13 |
 | Home Biosciences A new breed of biotech company A new breed of biotech company aiming to unlock scientific breakthrough by leveraging an asset-centric operating model Type: | 5 | 4 | 2 | 8 |
 | OBN (UK) Ltd The membership organisation supporting & bringing together UK’s life sciences companies, corporate partners & investors OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors. Our 450+ member companies are located across the Golden Triangle and beyond, and benefit from our networking, partnering, purchasing, advising, and advocacy activities. OBN organises BioTrinity - Europe's Leading Investment and Biopartnering Conference, find out more at www.biotrinity.com. Networking Events, Partnering (BioTrinity), Advising: Cluster Analysis and Business Development, Group Purchasing Consortium, Advocacy, Conferences, BioTech, and Life Sciences Type: | 8 | 4 | 4 | 29 |
 | BioCentury Inc. The leading voice for decision makers throughout the global healthcare ecosystem. BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The … Type: | 10 | 4 | 8 | 77 |
 | Acteurs de La French Care [Automatic translation follows] The grouping of players who support and develop the health ecosystem in France! The grouping of players who support and develop the health ecosystem in France! Type: | 29 | 4 | 26 | 1 |
 | VITAL MEAT Sustainable, healthy and delicious cultivated meat 🌎🍴 VITAL MEAT is a cultivated meat start-up based out of Nantes, France 🇫🇷 Our mission is to reduce human impact on the environment by providing HEALTHY, DELICIOUS, ETHICAL and SUSTAINABLE meat to billions of people 🌎 Thanks to our scalable technology and a cost effective process, we are gearing up to commercialize our first chicken product 🐔! Type: | 13 | 4 | 10 | 13 |
 | Catsalyze We improve your enzymes. Catsalyze will revolutionize enzymatic biocatalyze. Our proprietary technology allows us to graft enzymes around a protein ring, which gives them strong advantages such as increased stability, solubility, efficiency but also the possibility of assembling these grafted rings to create perfectly colocalized enzymatic cascades. . So extremely effective. Our challenge? Transform biomass in a gentle and clean way and through accelullar enzymatic catalysis into chemical bricks classically petrosourced and synthesized with pollution. The future of chemistry passes through Catsalyze. Type: | 25 | 4 | 22 | 2 |
 | Forbion Impacting the future of medicine Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners. Today, to emphasize our value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages over €2.3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. … Type: | 6 | 4 | 3 | 61 |
 | Pixium Vision S.A. Innovating at the frontier of neuroscience : brain machine interfacing the Eye and the Brain - from photons to neurons ! One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission … Type: | 7 | 5 | 1 | 45 |
 | CONCILIO Your key to better care. Concilio gives you access to the best in health care. In a world where doctors are becoming super-specialized, it’s not always easy to obtain reliable information and to know exactly who to turn to for your specific medical issue. As the first digital medical concierge service, Concilio aims to democratize access to the best in health care. Wherever you are in the world, our dedicated medical team is there to help you every day with more than 5 000 pathologies. E-santé, Téléconsultation, Recherche de Médecins, Bilan Santé, téléconseil médical, télémédecine, Médecins généralistes, Médecins Spécialistes, Conciergerie … Type: | 16 | 5 | 9 | 40 |
 | NHS The NHS was launched in 1948. It was born out of a long-held ideal that good healthcare should be available to all, regardless of wealth – one of the NHS's core principles. With the exception of some charges, such as prescriptions, optical services and dental services, the NHS in England remains free at the point of use for all UK residents. This currently stands at more than 64.6 million people in the UK and 54.3 million people in England alone. The NHS in England deals with over 1 million patients every 36 hours. It covers everything, including antenatal screening, routine … Type: | 19 | 5 | 3 | 243,493 |
 | HLTH Where the future of health happens 🦄 Join us at HLTH 2024 on October 20-24, 2024 and ViVE 2024 on February 25-28, 2024. HLTH is the leading platform bringing together the entire health ecosystem, focused on health innovation and transformation. From unparalleled events with industry-leading speakers to inspirational digital content and mission-driven initiatives, HLTH creates a unique marketplace for the health community leading the dialogue and development of a better health ecosystem. Join us in transforming the next decade of health, together. Type: | 35 | 5 | 23 | 84 |
 | AlbionVC Backing visionary founders with long-term capital & scale-up expertise. Partners to B2B software & healthcare companies. AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority. Type: | 23 | 5 | 21 | 27 |
 | Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule … Type: | 8 | 5 | 4 | 78 |
 | MedTech in France [Automatic translation follows] We are the French medical technology companies, we innovate every day for patients! Created in 2013, MedTech in France currently brings together more than 40 French companies in the health MedTech sector. and telemedicine, optical technologies, surgical robotics, and even medical imaging. The Association develops concrete solutions to promote market access, innovations and highlight French excellence in medical technologies. It has also set itself the mission of creating French champions internationally. MedTech in France has set itself a triple ambition: > provide medical solutions for patients and caregivers > bring economic and organizational benefits to the health … Type: | 25 | 5 | 22 | 7 |
 | Enersens Enersens produces the best thermal barriers and additives to improve safety, energy efficiency and flame protection Enersens is a leading innovative company specializing in silica aerogel products. We develop and market high performance aerogel-based insulation materials. We aim to become the leader in these high performance materials to enable our customers and partners to achieve their own goals around global trends in energy efficiency, sustainability, electric mobility and clean energy. Our Skogar® products solve the thermal runaway problems of batteries for any type of electric vehicle or electric mobility. Their performance and finesse also make it possible to solve many … Type: | 24 | 5 | 22 | 7 |
 | Calm/Storm Entrepreneurship is a continuous storm Calm/Storm is an exclusive founder network and boutique venture capital firm. We focus on talents, not industries. We believe in lifelong learning & personal growth, empowering entrepreneurs with unique access to successful founders. We are a fund built by founders for founders. Type: | 16 | 5 | 15 | 34 |
 | HealthTech For Care An endowment fund to support and promote access to care for all patients as well as new medical and drug technologies. The HealthTech For Care endowment fund has three essential missions: - fostering the growth and development of the entire health ecosystem, - advocating for the advancement of innovative therapies and treatments to benefit patients, - promoting enhanced access to care for patients within the European healthcare ecosystem. The HealthTech For Care endowment fund has been founded by France Biotech. Health Type: | 22 | 5 | 20 | 8 |
 | La Course des Lumières [Automatic translation follows] Together, let's light up the night against illness and for all sick people! Created in 2010, the Race of Lights is a national awareness event around the fight against disease. Since its creation, more than a million euros have been collected for the benefit of health organizations (foundations, hospitals, patient associations, etc.). Accessible to all, the event brings together more than 15,000 participants and 200 companies each year. Each participant, runner or walker, symbolically carries a luminous object to “light the night against illness and for all sick people”. solidarity, sport, running, walking, and team-building Type: | 5 | 5 | 1 | 1 |
 | ISALT [Automatic translation follows] Financing the new French industry and meeting the challenge of transitions “Our objective is to help French companies grow through long-term investment” ISALT is a portfolio management company whose mission is to invest long-term in the capital of listed or unlisted French companies. Since its creation in 2020, ISALT has set itself the ambition of developing a long-term investment platform with the aim of providing stable and constructive capital to French companies operating in key sectors for our economy. As such, it implements an investment strategy which consists of taking significant, long-term stakes in the capital of … Type: | 7 | 5 | 2 | 20 |
 | Sensorion Our mission: find solutions for hearing disorders Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs … Type: | 12 | 6 | 6 | 70 |
 | Eight Roads We back and partner with game-changing technology and healthcare companies in China, Europe, India, Japan and the US. Eight Roads Ventures is a global venture capital firm backed by Fidelity that helps entrepreneurs scale. We back and partner with game-changing technology and healthcare companies. With a presence in China, Europe, India and Japan, our global platform has 50+ years of venture investing experience, $11 Bn in AUM, over 300 portfolio companies and 60+ IPOs. Healthcare, Biosciences & Life Sciences, Consumer Technology, Internet & e-Commerce, FinTech & FinServ, Telecommunications, Food & Agriculture, Education and Skills Development, Enterprise Tech, Pharmaceuticals, Edu Tech, … Type: | 32 | 6 | 19 | 206 |
 | MATWIN French Accelerator dedicated to innovation in oncology MATWIN (Maturation & Accelerating Translation With INdustry) est un programme accélérateur pour développer la recherche translationnelle en cancérologie et faciliter le transfert des innovations vers les patients. Son objectif principal est d'accompagner des projets innovants (issus de laboratoires académiques ou portés par des startups) et présentant un fort potentiel de développement en favorisant des partenariats précoces. Le programme s’appuie sur un partenariat avec de grands laboratoires engagés en oncologie (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, Gilead, GlaxoSmithKline, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) et l’ensemble des acteurs soucieux de … Type: | 49 | 6 | 45 | 7 |
 | EuropaBio - the European Association for Bioindustries Innovative biotechnology, benefiting people and planet. EuropaBio, the European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. EuropaBio and its members are committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy. Type: | 21 | 6 | 18 | 29 |
 | Predict4Health AI-powered Precision Medicine for Organ Failure Our mission is to improve patients’ live and healthcare systems by postponing organ failure with the power of AI. 💪 Our products : 📊 A Decision making tool based on iBox : Predigraft helps physicians monitor transplanted patients by providing allograft survival prognosis. 📱 A Smart telemonitoring of chronic patients : Apilife is a fully connected platform acting as a medical hub for patients and their medical teams. 🧬 A Digital Biomarker for clinical trials : Our technology can be used to design clinical trials and to assess kidney allograft survival. Medicine, Machine Learning, … Type: | 40 | 6 | 30 | 28 |
 | Dieter von Holtzbrinck Ventures DvH Ventures | Investing early in Europe's most passionate founders. Dieter von Holtzbrinck Ventures (DvH Ventures) is one of Europe's leading early stage investors. As an entrepreneurial venture capitalist, DvH Ventures invests in emerging technology companies and builds successful investment clusters in areas such as Digital Health, Education, DeepTech or Climate Tech/ESG. Founded in 2014, partners Duc Quyen Tran, Peter Richarz and Fabian von Trotha manage several venture capital funds from their Cologne office. In addition to financial investments, DvH Ventures supports its portfolio companies with management expertise, in-depth industry knowledge and an international investor network. An exclusive media-for-equity programme … Type: | 25 | 6 | 18 | 10 |
 | M&M Conseil [Automatic translation follows] Public affairs - Institutional relations M&M Conseil has specialized in the organization of institutional events and public affairs consulting for more than 25 years. Close to French and European institutions, we organize key meetings between public, private and institutional stakeholders. Public Affairs Consulting, Institutional Communication, Events, and Public Relations Type: | 86 | 6 | 83 | 9 |
 | Inotrem Control innate immunity Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases. Tags: FrenchTech120 Type: | 7 | 6 | 1 | 34 |
 | Frst We are the first believers Frst is a Day One venture firm focused on supporting a new generation of French entrepreneurs with global ambitions. €200m+ AUMA invested in 50+ companies to date. Full portfolio on frst.vc Type: | 7 | 6 | 0 | 6 |
 | Dechert LLP Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors. © 2024 Dechert LLP. All rights reserved. This information should not be considered as legal opinions on specific facts or as … Type: | 10 | 6 | 5 | 2,229 |
 | MSInsight Unlocking the Power of Genomics: Advancing Cancer Care and Precision Medicine MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for … Type: | 32 | 6 | 31 | 6 |
 | Ecofi [Automatic translation follows] Active for the future Management that influences tomorrow In 1972 our first Sicav was born, which has since become Epargne Ethique Flexible. 1st sharing fund in Europe created in 1983, launch of our solidarity fund in 2002, range of 100% SRI* funds in 2019, first French management company to adopt the status of mission-driven company in 2020... Ecofi works to daily to combine financial performance and respect for People and the Planet. This commitment has only grown over the years. Today, Ecofi is more than ever committed to the long term, combining control, involvement and sincerity to … Type: | 38 | 7 | 22 | 95 |
 | Merieux Equity Partners Invested Investors Merieux Equity Partners is a multistage investment manager specialized in the healthcare & nutrition sectors via two dedicated platforms: Venture and Growth/Buyout. As an independent General Partner - registered under the French Financial Markets Authority AMF ("Autorité des Marchés Financiers") - Merieux Equity Partners currently manages 5 main funds, representing more than €1 billion of Commitments, and has supported over 45 companies in Europe and North America since its creation - in Venture Capital and Growth/Buyout. Our passion is to work alongside entrepreneurs and companies with an ambitious growth plan, offering them privileged access to our sector-expertise and … Type: | 9 | 7 | 5 | 39 |
 | Index Ventures Index helps the most ambitious entrepreneurs turn bold ideas into global businesses. Index Ventures partners with exceptional entrepreneurs – those with unique insight who are intrinsically driven to make their vision a reality. We help them turn their bold ideas into global businesses, and through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale up journey, we forge deep and long-lasting relationships with founders and their … | 11 | 7 | 3 | 114 |
 | Palais de Tokyo [Automatic translation follows] Contemporary art center, Paris 📍 🔛 Mohamed Bourouissa, Dislocations, Touch the insane, Past disquiet With its 22,000 m2, the Palais de Tokyo stands out through its energy as one of the largest contemporary art centers in Europe. It encourages contemporary creation with an eclectic and inventive program around emerging and established artists from all backgrounds. contemporary art, exhibitions, performances, and concerts Type: | 13 | 7 | 7 | 163 |
 | Marsh We help our clients and colleagues grow — and our communities thrive — by protecting and promoting Possibility. We help our clients and colleagues grow — and our communities thrive — by protecting and promoting Possibility. We seek better ways to manage risk and define more effective paths to the right outcome. We go beyond risk to rewards for our clients, our company, our colleagues, and the communities in which we serve. Marsh is the world’s leading insurance broker and risk advisor. With over 45,000 colleagues operating in 130 countries, Marsh serves commercial and individual clients with data-driven risk solutions … Type: | 10 | 7 | 3 | 12 |
 | STAT Reporting from the frontiers of health and medicine. Reporting from the frontiers of health and medicine We take you inside the science labs and hospitals, biotech boardrooms and political backrooms. We dissect crucial discoveries. We examine controversies and puncture hype. We hold individuals and institutions accountable. We introduce you to the power brokers and personalities who are driving a revolution in human health. These are the stories that matter to us all. Get access to exclusive content: http://www.statnews.com. Follow us on Twitter @statnews and on Facebook at facebook.com/statnews news, science news, medicine, health, biotech, pharma, health tech, covid, hospitals, and … Type: | 22 | 7 | 12 | 323 |
 | TISSIUM Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully … Tags: FrenchTech120 Type: | 11 | 7 | 5 | 122 |
 | Micropep Technologies Micropep is an innovative plant biotechnology company developing the next generation of biological crop protection solutions based on the incredible potential of micropeptides; short natural peptide molecules that target and regulate plant genes and proteins. Type: | 13 | 7 | 5 | 50 |
 | Institut de la Vision [Automatic translation follows] From the movement of knowledge to the therapeutic approaches of tomorrow Built in the heart of the National Hospital of 15-20, the Vision Institute is one of the largest integrated research centers on vision diseases in Europe. Designed as a place of gathering and exchange, it brings together fundamental, clinical and industrial research on the same site, thus promoting the sharing of concepts and techniques, the meeting of complementary skills and expertise and the emergence of new avenues of research. Researchers, doctors and manufacturers work together to discover and validate new therapies, preventive solutions, as well as … Type: | 20 | 7 | 9 | 229 |
 | Moon Surgical Empowering the Surgeon Moon Surgical aims to augment the surgeon with leaps forward in computer vision, haptics, and robotics. medical device, minimally invasive surgery, digital surgery, comanipulation, AI, Machine Learning, Surgery, Laparoscopy, and Surgical Robotics Tags: FrenchTech2030 Type: | 13 | 7 | 7 | 58 |
 | RebrAIn ReBrain standardizes targeting for DBS and brain lesion surgeries in Parkinson and essential tremor diseases RebrAIn offers a precise targeting technology for Deep Brain Stimulation (DBS). This is achieved through an algorithm based on Artificial Intelligence and a collaborative health data registry. With this innovative technology, developed to effectively identify the areas of the brain to be treated, ReBrain simplifies and standardizes DBS by reducing the risks and making it less traumatic, thus allowing more patients worldwide to be treated. Type: | 12 | 7 | 6 | 12 |
 | Jolt Capital Scaling responsible deeptech companies Jolt Capital SAS is a fully independent Private Equity firm authorized and regulated by AMF (Autorité des Marchés Financiers) that specialises in Technology, targeting investments into companies with revenues between €10m and €50m. Jolt Capital generates returns for its investors by enabling mid-sized technology-rich companies with strong fundamentals to execute their growth strategies, in sectors that offer good exit potential across software and hardware alike (cybersecurity, sensors, photonics, industrial processes, new energy systems, applied AI, robotics...) In providing growth capital to our portfolio companies, we support their scaling in new markets, new capacities and new acquisitions, … Type: | 89 | 8 | 86 | 33 |
 | Cardiologs AI Serving Cardiology Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence. Machine Learning, Big Data, MedTech, Cardiology, Artificial Intelligence, ECG analysis, Holter analysis, and SaaS Type: | 13 | 8 | 3 | 89 |
 | Niryo Niryo is a French startup designing collaborative #robots for universities, engineering schools, R&D & training centers. Niryo is a French startup designing desktop collaborative #robots for universities, engineering schools, training centers and research centers. Its reality? Democratizing cobotics and allowing its accessibility, while promoting a new vision for industry tinted with reason, humanity, durability and resilience. To keep on materializing this ambition, a team of forty passionate develop cutting edge hardware and software. This way, professionals are free to automate, research and train without a hassle. Embeddable in a variety of ecosystems, Niryo's cobots promote the awareness of a world … Type: | 43 | 8 | 15 | 40 |
 | MaaT Pharma The leading microbiome company in oncology MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process … Type: | 25 | 8 | 21 | 76 |
 | The Carlyle Group Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $426 billion of assets under management, Carlyle’s purpose is to invest wisely and create value on behalf of our investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,200 people in 28 offices across four continents. Type: | 9 | 8 | 0 | 2,559 |
 | Principles for Responsible Investment The UN-supported Principles for Responsible Investment, the world’s leading proponent of responsible investment. The Principles for Responsible Investment (PRI) is an investor initiative in partnership with UNEP FI and the UN Global Compact. Founded in 2006 and supported by the United Nations, the PRI has become the leading network for investors demonstrating their commitment to responsible ownership and long-term, sustainable returns. Pension funds, insurance companies, sovereign/development funds, investment managers and service providers make up the PRI network. Our goal is to grow investor interest in environmental, social and corporate governance issues (ESG), share best practice and support signatory needs in … Type: | 9 | 8 | 1 | 314 |
 | Amolyt Pharma Advancing peptides for the treatment of rare endocrine and related diseases Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. Hypoparathyroidism, Endocrinology, Metabolic Disease, Therapeutic Peptides, … Tags: FrenchTech2030 Type: | 9 | 8 | 1 | 62 |
 | Esquire magazine The most stylish and substantial men’s magazine. A one-stop shop for lifestyle advice – cars, culture, grooming, gadgets, food, fashion and more – and a showcase for brilliant journalism and photography. Esquire is intelligent, irreverent and unapologetically masculine. Type: | 10 | 8 | 10 | 286 |
 | Quantum Surgical Standardize minimally invasive liver cancer treatment Quantum Surgical is a French medical robotics company founded in Montpellier, France. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the … Tags: FrenchTech2030 Type: | 36 | 8 | 31 | 116 |
 | datacraft [Automatic translation follows] The data scientists club datacraft allows an exchange of best practices between data experts. It is a unique Club model, inspired by companionship, and designed to allow data scientists/data engineers to train among peers and enable companies to accelerate their AI/data projects. Access to the Club is through an annual membership. Type: | 47 | 8 | 35 | 17 |
 | BIOKET Bioeconomy Key Enabling Technologies platform Process & Technology innovations for biobased solutions to food, feed, chemicals, biomaterials and bioenergies Trois-Rivières (QC), Canada -- May 23th-25th, 2023 -- Biomass is a wonderful ressource to be transformed into chemicals, biobased materials, food and feed ingredients or energy. Still, adaptation and optimisation of transformation processes and technologies is a real challenge in order to valorise all biomass fraction in a circular approach. In the context of Industry 4.0, the circular economy and the need for an optimal valorization of renewable resources, BIOKET is the only European conference dedicated to bio-based technologies and processes. Innovative Processes, Biotechnology, Green Chemistry, … Type: | 28 | 9 | 22 | 2 |
SMB